Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2009
11/24/2009US7622485 administering plant alkaloids such as 1-deoxy-galactonojirimycin and related compounds for prophylaxis of Fabry's disease
11/24/2009US7622484 Such as asthma or chronic obstructive pulmonary disease; a corticoid such as mometasone furoate and 5-(1-hydroxy-2-((5,6-diethylindan-2-yl)amino)ethyl)8-hydroxy-1,2-dihydroquinolin-2-one or salt such as maleate
11/24/2009US7622483 Administering an aminoindanyl derivative and; a steroid, dopamine receptor agonist or an anticholinergic or antimuscarinic agent; respiratory system disorders, antiallergens, chronic obstructive pulmonary disease, adult respiratory distress syndrome, bronchitis
11/24/2009US7622482 anticancer agents; tyrosine kinase inhibitors based on pyrazole-3-amine linked through amine to fused heterocyclic ring such as benzimidazole, or imidazo[4,5-b]pyridine; e.g. N-(5-cyclopropyl-1H-pyrazol-3-yl)-3-(1-(4-fluorophenyl)ethyl)-3H-imidazo[4,5-b]pyridin-5-amine
11/24/2009US7622481 Gramnegative and Grampositive bacterial infections; substituted Piperidine derivatives specially optionally substituted pyrido [3,2, -b][1,4] thiazin-yl; 6-({(3R,4S)-3-Fluoro-1-[(R)-2-hydroxy-2-(2-methoxy-quinolin-8-yl)-ethyl]-piperidin-4-ylamino }-methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one; nontoxic
11/24/2009US7622480 Azaindolylpiperidine derivatives as antihistaminic and antiallergic agents
11/24/2009US7622479 For example, 2-(1,3-benzodioxol-5-yl)-6-phenyl-1H-imidazo[4,5-b]pyridinetyrosine; kinase-inhibiting activity; use in treatment of breast cancer, prostate cancer, lung cancer or pancreatic carcinoma
11/24/2009US7622478 Therapy for prostate cancer
11/24/2009US7622476 1-allyl-( 5R,8S,10R)-terguride; antagonistic properties to 5-HT2 receptors for the prevention of migraine-related headache, Parkinson's disease, disorders of the thrombocyte function
11/24/2009US7622475 3-{[(4-pyrazol-1-yl-benzyl)-(pyridine-3-sulfonyl)-amino]methyl}phenoxy)-acetic acid isopropyl ester; for reducing intraocular pressure in treating glaucoma, in a mammal
11/24/2009US7622474 Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis
11/24/2009US7622473 'N-(2-chloro-6-methylphenyl)-2-[[(6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamides metabolites
11/24/2009US7622472 Combination of Src kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases
11/24/2009US7622471 Pyrazole derivatives having a pyridazine and pyridine functionality
11/24/2009US7622470 Treatment of T-cell lymphoma using 10-propargyl-10-deazaaminopterin
11/24/2009US7622469 2,4-diamino-1,3,5-triazine derivatives
11/24/2009US7622468 Kinesin spindle protein inhibitor; antiproliferative agents; anticancer agents; 4-(2,5-difluorophenyl)-N-3-fluoropyrrolidin-3-yl)-2-hydroxymethyl-2-phenyl-2,5-diphdro-1N-pyrrol-1-carboxamide
11/24/2009US7622467 Aryl aniline derivatives as β2 adrenergic receptor agonists
11/24/2009US7622466 morpholin-4-yl-[5-(3-piperidin-1-yl-propoxy)-1H-pyrrolo[2,3-b]pyridin-2-yl]-methanone; treatment of obesity-related disorders such as diabetes, Syndrome X, or atherosclerotic disease and related disorders such as hypertriglyceridemia and hypercholesteremia
11/24/2009US7622465 Costunolide derivatives
11/24/2009US7622464 5-[({[({(2S)-4-[(3,4-dichlorophenyl)methyl]-2-morpholinyl}methyl)amino]carbonyl}amino)methyl]-N-methyl-3-furancarboxamide; free of N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-N'-(2-furylmethyl)urea; CCR3/chemokine recetptor/ antagonists
11/24/2009US7622463 Pyrimidinohydrodiazepinones, e.g., 2-(1,6-dihydro-4-methyl-6-oxopyridin-3-ylamino)-9-cyclopentyl-8,9-dihydro-5,7,7-trimethyl-5H-pyrimido[4,5-b][1,4]diazepin-6(7H)-one; especially c-Met kinase inhibitors; anticancer agents
11/24/2009US7622462 Benzazepine derivatives and uses thereof
11/24/2009US7622461 Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
11/24/2009US7622459 alkaline deproteination and subsequent elimination of water-soluble components consists in that the so obtained insoluble glucan is subsequently hydrated by wet grinding; heat sterilizing, results in a fungal polysaccharide with the beta -(1,3)-D-bond in the principal chain
11/24/2009US7622458 Combination of ET-743 and a 5-fluorouracil pro-drug for cancer treatment
11/24/2009US7622456 Method on clinical applications in head neck cancer by using DSG3 molecule for predicting malignant degree of cancer, serving as a molecular target and using RNA jamming sequence on inhibition-specific of DSG3 expression
11/24/2009US7622452 erythromycin compounds antibiotics for treating a bacterial infection, cystic fibrosis, respiratory system disorders; antiinflammatory agent; resist to stomach acid, bioavailability and reduced gastrointestinal side effects
11/24/2009US7622451 7-((2R,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyl-tetrahydro-2H-pyran-2-yloxy)-2H -chromen-2-one,N-(7-((3aR,4R,7R,7aR)-7-methoxy-6,6-dimethyl-2-oxo-tetrahydro-3aH-[1,3]dioxolo[4,5-c]pyran-4-yloxy)-2-oxo-2H-chromen-3-yl)acetamide; neurodegenerative disorders
11/24/2009US7622450 Flavone C-glycoside derivatives and compositions containing the derivatives
11/24/2009US7622449 4-[(2S,3R)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-1-(4-{3-[(methylsulfonyl)amino]propyl}phenyl)-4-oxoazetidin-2-yl]phenyl methyl beta -D-glucopyranosiduronate; useful for lowering plasma cholesterol levels, particularly low density lipoprotein, treating and preventing atherosclerosis
11/24/2009US7622448 Compositions suitable for topical application to the skin
11/24/2009US7622447 Use of glutathione synthesis stimulating compounds in reducing insulin resistance
11/24/2009US7622441 Comprising controlled substance and amino acid or polypeptide covalently bound to controlled substance in manner that renders controlled substance pharmacologically inactive; when delivered by oral route controlled substance is released in time-dependent manner by acid hydrolysis and/or enzyme cleavage
11/24/2009US7622306 Using plasma proteomic pattern for diagnosis, classification, prediction of response to therapy and clinical behavior, stratification of therapy, and monitoring disease in hematologic malignancies
11/24/2009US7622297 Administering a polynucleotide encoding a Mycrobacterium kansasii-derived alpha antigen; asthma, atopic dermatitis, allergic rhinitis, allergic conjunctivitis
11/24/2009US7622272 Treating cell proliferation disease; aberrant fetoplacental growth; cancer
11/24/2009US7622140 Processes and apparatus for extraction of active substances and enriched extracts from natural products
11/24/2009US7622138 gel comprising glycerol formal solvent, hydroxypropyl methylcellulose and a dissolved antibacterial agent Tobramycin, antifungal agent Terbinafine , and a steroid Betamethasone; controlled- or sustained-release; treating microbial infection of the skin, ear, or eye, especially for veterinary application
11/24/2009US7622136 Transparent transdermal nicotine delivery devices
11/24/2009US7622131 homo or copolysiloxanes terminated with bis/aminopropyldimethylsilanol or bis/hydroxypropyldimethylsilanol forms carbamate or urea linkage when reacted with a diisocyanate compound by forming carbamate or urea linkage; show unprecedented bulk material properties, used as gelling agent for silicone fluid
11/24/2009US7622130 contacting localized fat deposits associated with cellulite in a patient with an effective amount of up to 5% deoxycholic acid or sodium salt of deoxychloic acid and an excipient; do not require surgical procedures such as liposuction; does not include phosphatidyl choline
11/24/2009US7622117 3-deoxyglucosone and skin
11/24/2009US7622115 Treatment with anti-VEGF antibodies
11/24/2009US7622105 Conjugation product of a cytokine selected from tumor necrosis factor and interferon gamma and a ligand of CD13 receptor; antitumor agents
11/24/2009US7621939 Supplemental spine fixation device and method
11/24/2009CA2541832C Substituted 2h-[1,2,4]triazolo[4,3-a]pyrazines as gsk-3 inhibitors
11/24/2009CA2526145C C-glycoside derivatives or salts thereof for use as na+-glucose cotransporter inhibitors
11/24/2009CA2525924C Depigmenting agents
11/24/2009CA2507375C Use of rimexolone in the treatment of dry eye
11/24/2009CA2493336C Composition for solubilization of paclitaxel and preparation method thereof
11/24/2009CA2485926C (imidazol-1-yl-methyl)-pyridazine as nmda receptor blocker
11/24/2009CA2480668C Compositions comprising dietary fat complexer and methods for their use
11/24/2009CA2475712C Nicotinamide derivatives useful as pde4 inhibitors
11/24/2009CA2463915C A process for the preparation of the 14beta-hydroxy-baccatin iii-1,14-carbonate
11/24/2009CA2451124C Method for the preparation of escitalopram
11/24/2009CA2448030C Pharmaceutical composition comprising a lipase inhibitor and a sucrose fatty acid ester
11/24/2009CA2445678C Paroxetine controlled release compositions
11/24/2009CA2443774C Pharmaceutical dopamine glycoconjugate compositions and methods of their preparation
11/24/2009CA2434381C Naphthostyrils
11/24/2009CA2433197C Gyrase inhibitors and uses thereof
11/24/2009CA2431834C Methods and formulations for the treatment of female sexual dysfunction
11/24/2009CA2431355C 14.beta., 16,17-methylene steroids as novel androgens
11/24/2009CA2423930C Topical composition containing at least one vitamin d or one vitamin d analogue and at least one corticosteroid
11/24/2009CA2423836C Composition for the delivery of fentanyl
11/24/2009CA2422017C A transdermal electrotransport device for use in electrotransport drug delivery and method for manufacturing same
11/24/2009CA2421504C 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors
11/24/2009CA2419877C Storage stable tretinoin and 4-hydroxy anisole containing topical composition
11/24/2009CA2418968C Avermectin derivatives
11/24/2009CA2418794C Calcium receptor antagonists
11/24/2009CA2415383C New amidino derivatives and their use as thrombin inhibitors
11/24/2009CA2413337C Bioadhesive compositions and methods of preparation and use
11/24/2009CA2408144C Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
11/24/2009CA2392050C Pharmaceutical formulations containing zolmitriptan
11/24/2009CA2389378C 20-hete synthase inhibitor
11/24/2009CA2385882C Tyrosine derivatives
11/24/2009CA2385859C 2'-substituted 1,1'-biphenyl-2-carboxamides, processes for their preparation, their use as medicament, and pharmaceutical preparations comprising them
11/24/2009CA2383499C Drug delivery device
11/24/2009CA2378379C Fast-release extrudates and process for their production, and preparations obtainable therefrom
11/24/2009CA2377330C Combination therapy for effecting weight loss and treating obesity
11/24/2009CA2376870C Method for scavenging radicals with urocanic acid, derivatives and analogues
11/24/2009CA2373859C Blood carbonyl compound-trapping agent
11/24/2009CA2362411C Use of fluorinated triazoles for treating affective or attention disorders
11/24/2009CA2362153C Antimicrobial/endotoxin neutralizing polypeptide
11/24/2009CA2360039C Beta-d-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine for use in the treatment of hiv infections
11/24/2009CA2343120C Use of an anthracycline derivative for the treatment of a liver tumor
11/24/2009CA2343113C Anionic or cationic dendrimer antimicrobial or antiparasitic compositions
11/24/2009CA2338533C Method of treating an autoimmune disorder
11/24/2009CA2338342C Conjugates of dna interacting groups with steroid hormones for use as nucleic acid transfection agents
11/24/2009CA2274575C Preventive and curative agent for inflammatory bowel diseases
11/24/2009CA2264647C Fragmented polymeric hydrogels for adhesion prevention and their preparation
11/24/2009CA2256391C Anticoagulant peptidyl-arginine aldehyde derivatives
11/24/2009CA2247389C Agent for treatment of bladder troubles
11/24/2009CA2192592C Cross-linked polymers for removing bile salts from a patient
11/22/2009CA2666400A1 Composition and method of treating facial skin defect
11/19/2009WO2009140680A1 Novel compositions and methods for treating hyperproliferative diseases
11/19/2009WO2009140676A2 Compositions and methods for inhibition of retroviruses
11/19/2009WO2009140675A2 Combination therapy with an antitumor alkaloid
11/19/2009WO2009140665A2 Method of treatment
11/19/2009WO2009140642A2 Tricyclic antagonists of prostaglandin d2 receptors